Barcelona, Spain (ots/PRNewswire) - Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in HbA1c were demonstrated with 7 ...
Bagsværd, Denmark (ots/PRNewswire) - New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp® (fast-acting ...
Yoqneam, Israel (ots/PRNewswire) - Sofwave Medical Ltd., an emerging aesthetic device company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Sofwave system. The Sofwave device is indicated for use as a non-invasive aesthetic treatment to improve facial lines ...
Zürich (ots) - The "Volume Report" published today by Helsana elucidates the development of medical treatments. In Switzerland, increasing numbers of patients make use of medical treatments. As a result there is an increased need for coordination. General practitioners have less and less time to perform this role. The report finds great potential to meet these coordination needs in other health occupations. In its latest ...
- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - The designation is based on data from the ...
Prague, Mumbai and Ankleshwar, India (ots/PRNewswire) - Zentiva Group, a.s. announces the signing of a Business Transfer Agreement with Sanofi to acquire their manufacturing site in Ankleshwar, India. This acquisition will help ensure the continued supply of high-quality medicines to more patients by expanding the ...
- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations The information contained is not intended for ...
- Picture is available at AP Images (http://www.apimages.com) - Guangzhou, China (ots/PRNewswire) - On August 28-29, the BBS & Excellent Product Award Ceremony for Reducing Antibiotic Resistance for the Layer Industry was held in Guangzhou. China's Ministry of Agriculture and Rural Affairs reiterated that, starting ...
Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Lausanne, Switzerland (ots/PRNewswire) - Published online in the British Journal of ...
Amsterdam (ots/PRNewswire) - SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm's licensed rights for SALAGEN® (pilocarpine hydrochloride) ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - Data contributes to growing body of ...
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...
- Global and European real-world outcome analyses in non-selected atrial fibrillation (AF) patients on edoxaban, including those who are elderly with comorbidities, were reported at ESC Congress 2019 - At present, the Global ETNA-AF programme is the largest and most comprehensive repository of routine clinical ...
- Milestone contract signed between leading Chinese orthopaedic medtech supplier and Singapore based Asian subsidiary and hub of German world-market and technology leader in the area of bioabsorbable metallic implants for use in orthopaedic and trauma surgery - Contract volume of more than 100 million euros - ...
The procedure was performed by Joseph M. Berman, MD, an orthopedic surgeon at Arlington Orthopedics Associates (AOA), Arlington, TX Kfar Saba, Israel (ots/PRNewswire) - - CartiHeal (http://www.cartiheal.com/), developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first ...
- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful percutaneous coronary ...
Two patients were enrolled and operated on by sports medicine surgeon Andreas Gomoll, MD Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the successful enrollment and ...
Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland (ots/PRNewswire) - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development ...
London (ots/PRNewswire) - - New affordable, modular, mid-scale clinical chemistry, immunoassay and hematology range with sample selection and transport systems, making powerful automation accessible to growing labs - Hematology system uses unique combination of ultra-high definition imaging, artificial intelligence (AI) and traditional methods to analyse thousands of blood cells per minute to improve turn-around time - ...
A community of medical professionals sharing ideas and solving problems Lausanne, Switzerland (ots/PRNewswire) - LigneSante (https://lignesante.com/) today announced their online communication platform for healthcare professionals. The desire to connect to a collective knowledge around the management of diseases, aware that very often the complexity of medical ...
- Revenues up 7.2% on the prior-year quarter to EUR 356.5m - Adjusted EBITDA at EUR 74.2m in second quarter of 2019 (Q2 2018: EUR 71.1m), excluding EUR 26.2m from derecognition of contingent purchase price components in connection with Sensile Medical acquisition - Revenue guidance confirmed without change; guidance on adjusted EBITDA at constant exchange rates for the financial year 2019 approximately EUR 295m (plus ...
Bremen, Germany (ots/PRNewswire) - Once again, Jacobs University performed excellently in a university ranking. In the 2019 Times Higher Education (THE) Young University Ranking for universities which are younger than 50 years, the international, English-language campus university ranks 26th out of 351 participating ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - On behalf of social security institutions, psychiatrists assess to what extent people with mental health problems are still able to work. However, the work capability assessments tend to be far too dissimilar. A new training course, conducted within the scope of an SNSF-funded study, has helped to reduce the differences. People who cannot work full-time anymore because of mental health problems are entitled ...
The new adjuvanted polio vaccine has been approved by the Danish Medicines Agency, and the WHO prequalification is expected by the end of 2019, enabling initial delivery of up to 100 million doses globally via UN agencies in 2020-2024 Copenhagen, Denmark (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY AJ Vaccines today announced that its adjuvanted IPV vaccine has ...
Not intended for UK or U.S. based media Darmstadt, Germany (ots/PRNewswire) - - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...